| Zacks Company Profile for Takeda Pharmaceutical Co. (TAK : NYSE) |
|
|
| |
| • Company Description |
| Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Number of Employees: 47,455 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $14.84 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,983,017 shares |
| Shares Outstanding: 3,181.92 (millions) |
| Market Capitalization: $47,219.74 (millions) |
| Beta: 0.23 |
| 52 Week High: $15.53 |
| 52 Week Low: $12.80 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-3.57% |
-7.18% |
| 12 Week |
0.88% |
-15.14% |
| Year To Date |
12.09% |
4.97% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Christophe Weber - Chief Executive Officer; President and Director
Masami Iijima - Chairman of the Board and Director
Milano Furuta - Chief Financial Officer and Director
Olivier Bohuon - Director
Jean-Luc Butel - Director
|
|
Peer Information
Takeda Pharmaceutical Co. (GSAC)
Takeda Pharmaceutical Co. (CASI)
Takeda Pharmaceutical Co. (ALCD.)
Takeda Pharmaceutical Co. (OMNN)
Takeda Pharmaceutical Co. (CGPI.)
Takeda Pharmaceutical Co. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 874060205
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
|
|
Share - Related Items
Shares Outstanding: 3,181.92
Most Recent Split Date: (:1)
Beta: 0.23
Market Capitalization: $47,219.74 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 3.72% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.49 |
Indicated Annual Dividend: $0.55 |
| Current Fiscal Year EPS Consensus Estimate: $1.71 |
Payout Ratio: 0.35 |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: 0.03 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/30/25 |
|
|
|
| |
